159 related articles for article (PubMed ID: 12846089)
1. [Tonocardin (doxazosin) in treating lower urinary tract symptoms].
Mazo EB; Chepurov DA
Urologiia; 2003; (3):15-6. PubMed ID: 12846089
[TBL] [Abstract][Full Text] [Related]
2. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
[TBL] [Abstract][Full Text] [Related]
3. Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
Gerber GS; Contreras BA; Rukstalis DB
Tech Urol; 1997; 3(3):164-7. PubMed ID: 9422449
[TBL] [Abstract][Full Text] [Related]
4. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
5. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
7. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
[TBL] [Abstract][Full Text] [Related]
8. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
[TBL] [Abstract][Full Text] [Related]
9. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
[TBL] [Abstract][Full Text] [Related]
10. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
[TBL] [Abstract][Full Text] [Related]
11. [Using doxasosine and finasteride combination in the treatment of prostate adenoma].
Bogdanov AB; Luk'ianov IV; Veliev EI
Urologiia; 2006; (5):59-63. PubMed ID: 17444154
[TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
14. Use of novel urodynamic parameters, detrusor contraction duration and detrusor contraction index, in men with lower urinary tract symptoms.
Turner CD; Kuznetsov D; Contreras BA; Gerber GS
Tech Urol; 1998 Sep; 4(3):136-40. PubMed ID: 9800891
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
16. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
Kirby RS
Br J Clin Pract Suppl; 1994 May; 74():23-8. PubMed ID: 7519438
[TBL] [Abstract][Full Text] [Related]
17. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia.
Kirby RS
Scand J Urol Nephrol Suppl; 1995; 168():29-33. PubMed ID: 7541549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
